Therapeutic Drug Monitoring of Olanzapine: The Combined Effect of Age, Gender, Smoking, and Comedication
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Therapeutic drug monitoring (TDM) data for the antipsychotic drug olanzapine were investigated with respect to concentration versus dose relationship, intraindividual versus interindividual variability, and the combined influence of patient characteristics on steady-state concentration. The study included 250 patients, with daily doses ranging from 2.5 to 30 mg. Median concentration to dose ratio was 2.1 (ng/mL)/(mg/d), with 90% of the distribution in a fivefold range. In the first subgroup of patients with two measurements at different doses (n = 21), data were in keeping with linear concentration versus dose relationship. In the second subgroup of patients with repeated measurements at a constant daily dose (n = 40), estimates of within-patient and between-patient variabilities were 30.5% and 49.4%, respectively. In the whole sample, multiple regression analysis of dose-normalized concentration revealed significant effects of time postdose (-18% per 12 hours delay, P < 0.05), age >/=60 years (+27%, P < 0.005), cigarette smoking (-12%, P < 0.05), and comedication with fluvoxamine (+74%, P < 0.001), paroxetine, fluoxetine, or sertraline (considered together, +32%, P < 0.05), venlafaxine (+27%, P < 0.05), and inducers of P450 enzymes (-40%, P < 0.001). The final model included a tendency for higher concentration associated with female gender (+11%, P = 0.07) and accounted for 27% of observed interindividual variability. When considering a worst-case scenario, an elderly, nonsmoking woman prescribed fluvoxamine comedication was predicted to reach a 4.6-fold higher olanzapine concentration than a young male smoker coadministered carbamazepine. The current study suggests that patients characterized by a combination of factors associated with altered metabolism may benefit from olanzapine TDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olanzapine: Pharmacokinetic and Pharmacodynamic Profile
Callaghan, J. T., Bergstrom, R. F., Ptak, L. R., & Beasley, C. M. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937030-00001 · Cited by 544 · cited 10×
“However, their combined effect has remained undocumented so far in large cohorts of patients receiving the drug for therapeutic purposes, despite the recommendation that dosage adjustment should be considered in patients characterized by a combination of factors associated with decreased metabolism (6,9).”
BackgroundResultInfluentialVolavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Drug glucuronidation in humans
Miners, J. O., & Mackenzie, P. I. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90065-t · Cited by 361 · cited 1×
“The fact that CYP1A2 and glucuronosyltransferases can be inhibited or induced by environmental factors, such as smoking, coffee, alcohol, and other diet components, can also be invoked (15,16).”
BackgroundSmoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective
Desai, H. D., Seabolt, J., & Jann, M. W. (2001) · CNS Drugs · doi:10.2165/00023210-200115060-00005 · Cited by 253 · cited 1×
“Similarly, the significantly lower concentration in cigarette smokers was in keeping with polycyclic aromatic hydrocarbons inducing CYP1A2 and glucuronosyltransferases (19,20).”
BackgroundFulton, B., & Goa, K. L. (1997) · Drugs · doi:10.2165/00003495-199753020-00007 · Cited by 250
Olanzapine: An Updated Review of its Use in the Management of Schizophrenia
Bhana, N., Foster, R. H., Olney, R., & Plosker, G. L. (2001) · Drugs · doi:10.2165/00003495-200161010-00011 · Cited by 217
Ring, B. J., Catlow, J., Lindsay, T. J., Gillespie, T., Roskos, L. K., Cerimele, B. J., Swanson, S. P., Hamman, M. A., & Wrighton, S. A. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12326-4 · Cited by 214 · cited 1×
“The flavin-containing monooxygenase FMO3, CYP1A2, and CYP2D6 are responsible for N-oxidation, N-desmethylation, and a minor 2-hydroxylation pathway, respectively (5).”
BackgroundDisposition and biotransformation of the antipsychotic agent olanzapine in humans.
Kassahun, K., Mattiuz, E. L., Nyhart, E. H., Obermeyer, B. D., Gillespie, T. A., Murphy, A., Rm, G., Tupper, D., Callaghan, J. T., & Lemberger, L. (1997) · PubMed · Cited by 211
Pharmacokinetics and drug interactions: update for new antipsychotics.
Ereshefsky, L. (1996) · PubMed · Cited by 211
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202 · cited 4×
“Inclusion criteria were as follows: (1) TDM request form provided full information about present dose, date of last dose adjustment, time of last intake, and time of venipuncture; and (2) time since last dose adjustment was at least 7 days, so that steady state was assumed (6).”
BackgroundInfluential
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Drug interactions with smoking
Kroon, L. A. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060414 · Cited by 345
Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs
Zaccara, G., & Perucca, E. (2014) · Epileptic Disorders · doi:10.1684/epd.2014.0714 · Cited by 305
Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review
Spina, E., & De Leon, J. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00017.x · Cited by 271
Clinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250
“ported co-medications, non-compliance, and intrinsic interindividual variability in drug metabolism and/or clearance (Gex-Fabry et al., 2003; Fellows et al., 2003).”
BackgroundInfluentialThe effect of variable cigarette consumption on the interaction with clozapine and olanzapine
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0209-9 · Cited by 178
Sex, Race, and Smoking Impact Olanzapine Exposure
Bigos, K. L., Pollock, B. G., Coley, K. C., Miller, D. D., Marder, S. R., Aravagiri, M., Kirshner, M. A., Schneider, L. S., & Bies, R. R. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007310385 · Cited by 177
Citrome, L., Stauffer, V. L., Chen, L., Kinon, B. J., Kurtz, D. L., Jacobson, J. G., & Bergstrom, R. F. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a289cb · Cited by 88
“Other studies also included assessments of the effects of comedication with antidepressants and/or anticonvulsants.(11,12) Evidence regarding the association of concentration and efficacy when olanzapine is dosed above 20 mg/d shows either no effect(13) or low predictive value.”
BackgroundPharmacokinetics of olanzapine long-acting injection: the clinical perspective
Heres, S., Kraemer, S., Bergstrom, R. F., & Detke, H. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000040 · Cited by 50
Metadata
- Authors
- Gex-Fabry, M., Balant-Gorgia, A. E., & Balant, L. P.
- Venue
- Therapeutic Drug Monitoring
- Published
- 2003-02
- Volume
- 25
- Issue
- 1
- Pages
- 46-53
- ISSN
- 0163-4356 (ISSN-L)
- OpenAlex
- W2333441088
- Cited by
- 167
- References
- 28
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.